Groningen, The Netherlands, 21 January 2016 – Polyganics, a privately held medical technology company focused on the commercialization of proprietary products and technologies for peripheral nerve repair, neurosurgery, general surgery, as well as ear, nose & throat surgery, today announced it has signed an exclusive distribution agreement with its strategic partner MicroAire Surgical Instruments LLC for the company’s entire peripheral nerve repair (PNR) portfolio in the US, Canada and Puerto Rico.
Rudy Mareel, CEO a.i. of Polyganics said, “It is a significant milestone to have closed such an agreement with MicroAire Surgical Instruments LLC. MicroAire is a well-known company in this arena with a dedicated sales force and an excellent track-record in marketing specialized devices for orthopedic and hand surgeons. This partnership will help us bring our products to patients at an accelerated pace.”
Greg Jones, General Manager of MicroAire Surgical Instruments LLC added, “With this partnership MicroAire has broadened its product portfolio with new high quality devices in the area of peripheral nerve repair. With the addition of the NEUROLAC® nerve conduit and the VIVOSORB® surgical sheet, we can offer our surgeons a wide portfolio of peripheral nerve repair products to enhance patient care.”
Polyganics is a medical technology company with multiple versatile polymer platforms. The Company develops, manufactures and commercializes innovative bioresorbable medical devices that facilitate tissue repair and regeneration.
Polyganics’ portfolio includes products developed in-house and in collaboration with leading medical technology companies and academic centers of excellence. In the Peripheral Nerve Repair (PNR) and neurosurgery field, the portfolio includes two marketed products: VIVOSORB® for minimizing unwanted tissue adhesions after surgery; and NEUROLAC® for supporting PNR following hand surgery. Products in development include a product-candidate for preventing the formation of neuromas following amputation or other injury, and a sealant for the dural membrane, for use post brain surgery.
In 2014, the Company sold its Ear, Nose & Throat (ENT) surgery business unit (the NASOPORE® product family including HEMOPORE®, SINUPORE® and OTOPORE®) to US Company Stryker, one of the world’s leading medical technology companies. NASOPORE®, a reliable, easy-to-use, nasal wound care dressing made of biodegradable foam, has been used in over 2.5m procedures globally.
Polyganics has a supportive shareholder base, including the investment agency of the Northern Netherlands (NOM), and the University of Groningen. The Company has a research partnership with the non-profit organization the Brain Technology Institute, an international group of neurosurgeons.
Polyganics is profitable and privately held. The Company is based in Groningen, The Netherlands, a center of biomedical engineering excellence, in an ISO 13485-certified manufacturing facility. The Company’s polymer platform technologies are protected by a broad portfolio of patents and its products have received FDA, CE, CFDA and other international registrations.